Biomarkers of Helicobacter pylori-associated gastric cancer

References

• Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333:32 - 41; http://dx.doi.org/10.1056/NEJM199507063330107; PMID: 7776992
   PubMed Web of Science ®Google Scholar
• Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 2005; 54:209 - 41; http://dx.doi.org/10.1016/j.critrevonc.2005.01.002; PMID: 15890270
   PubMed Web of Science ®Google Scholar
• Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241:27 - 39; PMID: 15621988
   PubMed Web of Science ®Google Scholar
• Ohta H, Noguchi Y, Takagi K, Nishi M, Kajitani T, Kato Y. Early gastric carcinoma with special reference to macroscopic classification. Cancer 1987; 60:1099 - 106; http://dx.doi.org/10.1002/1097-0142(19870901)60:5<1099::AID-CNCR2820600530>3.0.CO;2-F; PMID: 3607727
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893 - 917; http://dx.doi.org/10.1002/ijc.25516; PMID: 21351269
   PubMed Web of Science ®Google Scholar
• Torres J, Correa P, Ferreccio C, Hernandez-Suarez G, Herrero R, Cavazza-Porro M, et al. Gastric cancer incidence and mortality is associated with altitude in the mountainous regions of Pacific Latin America. Cancer Causes Control 2013; 24:249 - 56; http://dx.doi.org/10.1007/s10552-012-0114-8; PMID: 23224271
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498 - 504; http://dx.doi.org/10.1016/S0140-6736(96)07492-2; PMID: 9167458
   PubMed Web of Science ®Google Scholar
• Lauren P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64:31 - 49; PMID: 14320675
   PubMedGoogle Scholar
• Carneiro F. Hereditary gastric cancer. Pathologe 2012; 33:Suppl 2 231 - 4; http://dx.doi.org/10.1007/s00292-012-1677-6; PMID: 23052347
   PubMedGoogle Scholar
• Yakirevich E, Resnick MB. Pathology of gastric cancer and its precursor lesions. Gastroenterol Clin North Am 2013; 42:261 - 84; http://dx.doi.org/10.1016/j.gtc.2013.01.004; PMID: 23639640
   PubMed Web of Science ®Google Scholar
• Chan AO, Huang C, Hui WM, Cho CH, Yuen MF, Lam SK, et al. Stability of E-cadherin methylation status in gastric mucosa associated with histology changes. Aliment Pharmacol Ther 2006; 24:831 - 6; http://dx.doi.org/10.1111/j.1365-2036.2006.03032.x; PMID: 16918887
   PubMed Web of Science ®Google Scholar
• Chan AO, Lam SK, Wong BC, Wong WM, Yuen MF, Yeung YH, et al. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003; 52:502 - 6; http://dx.doi.org/10.1136/gut.52.4.502; PMID: 12631658
   PubMed Web of Science ®Google Scholar
• Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis 2012; 13:2 - 9; http://dx.doi.org/10.1111/j.1751-2980.2011.00550.x; PMID: 22188910
   PubMed Web of Science ®Google Scholar
• Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19:449 - 90; http://dx.doi.org/10.1128/CMR.00054-05; PMID: 16847081
   PubMed Web of Science ®Google Scholar
• Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347:1175 - 86; http://dx.doi.org/10.1056/NEJMra020542; PMID: 12374879
   PubMed Web of Science ®Google Scholar
• Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127 - 31; http://dx.doi.org/10.1056/NEJM199110173251603; PMID: 1891020
   PubMed Web of Science ®Google Scholar
• Areia M, Carvalho R, Cadime AT, Rocha Gonçalves F, Dinis-Ribeiro M. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter 2013; In press http://dx.doi.org/10.1111/hel.12050; PMID: 23566268
   PubMed Web of Science ®Google Scholar
• Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 2010; 116:2941 - 53; http://dx.doi.org/10.1002/cncr.25030; PMID: 20564399
   PubMed Web of Science ®Google Scholar
• Yeh JM, Kuntz KM, Ezzati M, Goldie SJ. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer 2009; 124:157 - 66; http://dx.doi.org/10.1002/ijc.23864; PMID: 18823009
   PubMed Web of Science ®Google Scholar
• Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, et al. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA 2013; 309:578 - 86; http://dx.doi.org/10.1001/jama.2013.311; PMID: 23403682
   PubMed Web of Science ®Google Scholar
• Diamandis EP. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?. BMC Med 2012; 10:87; http://dx.doi.org/10.1186/1741-7015-10-87; PMID: 22876833
   PubMed Web of Science ®Google Scholar
• Pavlou MP, Diamandis EP, Blasutig IM. The long journey of cancer biomarkers from the bench to the clinic. Clin Chem 2013; 59:147 - 57; http://dx.doi.org/10.1373/clinchem.2012.184614; PMID: 23019307
   PubMed Web of Science ®Google Scholar
• Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann Intern Med 2009; 151:121 - 8; http://dx.doi.org/10.7326/0003-4819-151-2-200907210-00009; PMID: 19620164
   PubMed Web of Science ®Google Scholar
• Romero-Gallo J, Harris EJ, Krishna U, Washington MK, Perez-Perez GI, Peek RM Jr.. Effect of Helicobacter pylori eradication on gastric carcinogenesis. Lab Invest 2008; 88:328 - 36; http://dx.doi.org/10.1038/labinvest.3700719; PMID: 18180700
   PubMed Web of Science ®Google Scholar
• Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al, China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291:187 - 94; http://dx.doi.org/10.1001/jama.291.2.187; PMID: 14722144
   PubMed Web of Science ®Google Scholar
• Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102:605 - 13; http://dx.doi.org/10.1093/jnci/djq099; PMID: 20413742
   PubMed Web of Science ®Google Scholar
• Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012; 367:1998 - 2005; http://dx.doi.org/10.1056/NEJMoa1206809; PMID: 23171096
   PubMed Web of Science ®Google Scholar
• Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med 2003; 138:644 - 50; http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00012; PMID: 12693887
   PubMed Web of Science ®Google Scholar
• Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004; 4:309 - 14; http://dx.doi.org/10.1038/nrc1322; PMID: 15057290
   PubMed Web of Science ®Google Scholar
• Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005; 5:142 - 9; http://dx.doi.org/10.1038/nrc1550; PMID: 15685197
   PubMed Web of Science ®Google Scholar
• Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012; 9:e1001216; http://dx.doi.org/10.1371/journal.pmed.1001216; PMID: 22675273
   PubMed Web of Science ®Google Scholar
• Agréus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012; 47:136 - 47; http://dx.doi.org/10.3109/00365521.2011.645501; PMID: 22242613
   PubMed Web of Science ®Google Scholar
• Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990; 50:4737 - 40; PMID: 2369748
   PubMed Web of Science ®Google Scholar
• Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109:138 - 43; http://dx.doi.org/10.1002/ijc.11680; PMID: 14735480
   PubMed Web of Science ®Google Scholar
• Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985; 35:173 - 7; http://dx.doi.org/10.1002/ijc.2910350206; PMID: 3871738
   PubMed Web of Science ®Google Scholar
• Kim N, Jung HC. The role of serum pepsinogen in the detection of gastric cancer. Gut Liver 2010; 4:307 - 19; http://dx.doi.org/10.5009/gnl.2010.4.3.307; PMID: 20981206
   PubMed Web of Science ®Google Scholar
• Sipponen P, Graham DY. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol 2007; 42:2 - 10; http://dx.doi.org/10.1080/00365520600863720; PMID: 17190755
   PubMed Web of Science ®Google Scholar
• Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. Scand J Gastroenterol 2008; 43:1448 - 55; http://dx.doi.org/10.1080/00365520802273025; PMID: 18663663
   PubMed Web of Science ®Google Scholar
• Väänänen H, Vauhkonen M, Helske T, Kääriäinen I, Rasmussen M, Tunturi-Hihnala H, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003; 15:885 - 91; http://dx.doi.org/10.1097/00042737-200308000-00009; PMID: 12867799
   PubMed Web of Science ®Google Scholar
• Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Figueroa LS, Halperin D, et al. Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomarkers Prev 2001; 10:107 - 12; PMID: 11219766
   PubMed Web of Science ®Google Scholar
• Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006; 9:245 - 53; http://dx.doi.org/10.1007/s10120-006-0397-0; PMID: 17235625
   PubMedGoogle Scholar
• Miki K, Fujishiro M, Kodashima S, Yahagi N. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009; 21:78 - 81; http://dx.doi.org/10.1111/j.1443-1661.2009.00839.x; PMID: 19691778
   PubMed Web of Science ®Google Scholar
• Varis K, Sipponen P, Laxén F, Samloff IM, Huttunen JK, Taylor PR, et al, Helsinki Gastritis Study Group. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Scand J Gastroenterol 2000; 35:950 - 6; http://dx.doi.org/10.1080/003655200750023011; PMID: 11063155
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Bardram L, Hilsted L, Poitras P, Goetze JP. Pitfalls in diagnostic gastrin measurements. Clin Chem 2012; 58:831 - 6; http://dx.doi.org/10.1373/clinchem.2011.179929; PMID: 22419747
   PubMed Web of Science ®Google Scholar
• Cao Q, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis 2007; 8:15 - 22; http://dx.doi.org/10.1111/j.1443-9573.2007.00271.x; PMID: 17261130
   PubMed Web of Science ®Google Scholar
• Shiotani A, Iishi H, Uedo N, Kumamoto M, Nakae Y, Ishiguro S, et al. Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer 2005; 115:463 - 9; http://dx.doi.org/10.1002/ijc.20852; PMID: 15688378
   PubMed Web of Science ®Google Scholar
• Inoue K, Fujisawa T, Haruma K. Assessment of degree of health of the stomach by concomitant measurement of serum pepsinogen and serum Helicobacter pylori antibodies. Int J Biol Markers 2010; 25:207 - 12
   PubMed Web of Science ®Google Scholar
• Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54:764 - 8; http://dx.doi.org/10.1136/gut.2004.055400; PMID: 15888780
   PubMed Web of Science ®Google Scholar
• Zhang X, Xue L, Xing L, Wang J, Cui J, Mi J, et al. Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community. Int J Cancer 2012; 130:1614 - 9; http://dx.doi.org/10.1002/ijc.26172; PMID: 21547904
   PubMed Web of Science ®Google Scholar
• Camorlinga-Ponce M, Flores-Luna L, Lazcano-Ponce E, Herrero R, Bernal-Sahagún F, Abdo-Francis JM, et al. Age and severity of mucosal lesions influence the performance of serologic markers in Helicobacter pylori-associated gastroduodenal pathologies. Cancer Epidemiol Biomarkers Prev 2008; 17:2498 - 504; http://dx.doi.org/10.1158/1055-9965.EPI-08-0289; PMID: 18768521
   PubMed Web of Science ®Google Scholar
• Janulaityte-Günther D, Kupcinskas L, Pavilonis A, Valuckas K, Wadström T, Andersen LP. Combined serum IgG response to Helicobacter pylori VacA and CagA predicts gastric cancer. FEMS Immunol Med Microbiol 2007; 50:220 - 5; http://dx.doi.org/10.1111/j.1574-695X.2007.00268.x; PMID: 17567283
   PubMed Web of Science ®Google Scholar
• Shiota S, Matsunari O, Watada M, Yamaoka Y. Serum Helicobacter pylori CagA antibody as a biomarker for gastric cancer in east-Asian countries. Future Microbiol 2010; 5:1885 - 93; http://dx.doi.org/10.2217/fmb.10.135; PMID: 21155667
   PubMed Web of Science ®Google Scholar
• Suzuki G, Cullings H, Fujiwara S, Hattori N, Matsuura S, Hakoda M, et al. Low-positive antibody titer against Helicobacter pylori cytotoxin-associated gene A (CagA) may predict future gastric cancer better than simple seropositivity against H. pylori CagA or against H. pylori.. Cancer Epidemiol Biomarkers Prev 2007; 16:1224 - 8; http://dx.doi.org/10.1158/1055-9965.EPI-06-1048; PMID: 17548689
   PubMed Web of Science ®Google Scholar
• Yamaoka Y, Kodama T, Kashima K, Graham DY. Antibody against Helicobacter pylori CagA and VacA and the risk for gastric cancer. J Clin Pathol 1999; 52:215 - 8; http://dx.doi.org/10.1136/jcp.52.3.215; PMID: 10450182
   PubMed Web of Science ®Google Scholar
• Flores-Luna L, Camorlinga-Ponce M, Hernandez-Suarez G, Kasamatsu E, Martínez ME, Murillo R, et al. The utility of serologic tests as biomarkers for Helicobacter pylori-associated precancerous lesions and gastric cancer varies between Latin American countries. Cancer Causes Control 2013; 24:241 - 8; http://dx.doi.org/10.1007/s10552-012-0106-8; PMID: 23184121
   PubMed Web of Science ®Google Scholar
• Epplein M, Zheng W, Xiang YB, Peek RM Jr., Li H, Correa P, et al. Prospective study of Helicobacter pylori biomarkers for gastric cancer risk among Chinese men. Cancer Epidemiol Biomarkers Prev 2012; 21:2185 - 92; http://dx.doi.org/10.1158/1055-9965.EPI-12-0792-T; PMID: 23035179
   PubMed Web of Science ®Google Scholar
• Gao L, Michel A, Weck MN, Arndt V, Pawlita M, Brenner H. Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res 2009; 69:6164 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-09-0596; PMID: 19602590
   PubMed Web of Science ®Google Scholar
• Gao L, Weck MN, Michel A, Pawlita M, Brenner H. Association between chronic atrophic gastritis and serum antibodies to 15 Helicobacter pylori proteins measured by multiplex serology. Cancer Res 2009; 69:2973 - 80; http://dx.doi.org/10.1158/0008-5472.CAN-08-3477; PMID: 19318564
   PubMed Web of Science ®Google Scholar
• Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O’Connor A, et al, European Society of Gastrointestinal Endoscopy, European Helicobacter Study Group, European Society of Pathology, Sociedade Portuguesa de Endoscopia Digestiva. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44:74 - 94; http://dx.doi.org/10.1055/s-0031-1291491; PMID: 22198778
   PubMed Web of Science ®Google Scholar
• Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, et al, Asia-Pacific Gastric Cancer Consensus Conference. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23:351 - 65; http://dx.doi.org/10.1111/j.1440-1746.2008.05314.x; PMID: 18318820
   PubMed Web of Science ®Google Scholar
• Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, et al, Asia Pacific Working Group on Gastric Cancer. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008; 9:279 - 87; http://dx.doi.org/10.1016/S1470-2045(08)70072-X; PMID: 18308253
   PubMed Web of Science ®Google Scholar
• Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 2012; 143:35 - 47, e2; http://dx.doi.org/10.1053/j.gastro.2012.05.003; PMID: 22580099
   PubMed Web of Science ®Google Scholar
• Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92 - 105; http://dx.doi.org/10.1101/gr.082701.108; PMID: 18955434
   PubMed Web of Science ®Google Scholar
• Hishida A, Matsuo K, Goto Y, Naito M, Wakai K, Tajima K, et al. Combined effect of miR-146a rs2910164 G/C polymorphism and Toll-like receptor 4 +3725 G/C polymorphism on the risk of severe gastric atrophy in Japanese. Dig Dis Sci 2011; 56:1131 - 7; http://dx.doi.org/10.1007/s10620-010-1376-1; PMID: 20721625
   PubMed Web of Science ®Google Scholar
• Kogo R, Mimori K, Tanaka F, Komune S, Mori M. Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res 2011; 17:4277 - 84; http://dx.doi.org/10.1158/1078-0432.CCR-10-2866; PMID: 21632853
   PubMed Web of Science ®Google Scholar
• Okubo M, Tahara T, Shibata T, Yamashita H, Nakamura M, Yoshioka D, et al. Association between common genetic variants in pre-microRNAs and gastric cancer risk in Japanese population. Helicobacter 2010; 15:524 - 31; http://dx.doi.org/10.1111/j.1523-5378.2010.00806.x; PMID: 21073609
   PubMed Web of Science ®Google Scholar
• Zhou F, Zhu H, Luo D, Wang M, Dong X, Hong Y, et al. A functional polymorphism in Pre-miR-146a is associated with susceptibility to gastric cancer in a Chinese population. DNA Cell Biol 2012; 31:1290 - 5; http://dx.doi.org/10.1089/dna.2011.1596; PMID: 22455393
   PubMed Web of Science ®Google Scholar
• Peng S, Kuang Z, Sheng C, Zhang Y, Xu H, Cheng Q. Association of microRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese population. Dig Dis Sci 2010; 55:2288 - 93; http://dx.doi.org/10.1007/s10620-009-1007-x; PMID: 19834808
   PubMed Web of Science ®Google Scholar
• Sun Q, Gu H, Zeng Y, Xia Y, Wang Y, Jing Y, et al. Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression. Cancer Sci 2010; 101:2241 - 7; http://dx.doi.org/10.1111/j.1349-7006.2010.01667.x; PMID: 20666778
   PubMed Web of Science ®Google Scholar
• Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol 2009; 24:652 - 7; http://dx.doi.org/10.1111/j.1440-1746.2008.05666.x; PMID: 19175831
   PubMed Web of Science ®Google Scholar
• Mostert B, Sieuwerts AM, Martens JW, Sleijfer S. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn 2011; 11:259 - 75; PMID: 21463236
   PubMed Web of Science ®Google Scholar
• Feng Y, Wang L, Zeng J, Shen L, Liang X, Yu H, et al. Fork head box M1 is overexpressed in Helicobacter pylori-induced gastric carcinogenesis and is negatively regulated by hsa-miR-370. Mol Cancer Res 2013; http://dx.doi.org/10.1158/1541-7786.MCR-13-0007; PMID: 23576572
   PubMed Web of Science ®Google Scholar
• Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 2012; 316:196 - 203; http://dx.doi.org/10.1016/j.canlet.2011.10.034; PMID: 22169097
   PubMed Web of Science ®Google Scholar
• Oertli M, Engler DB, Kohler E, Koch M, Meyer TF, Müller A. MicroRNA-155 is essential for the T cell-mediated control of Helicobacter pylori infection and for the induction of chronic Gastritis and Colitis. J Immunol 2011; 187:3578 - 86; http://dx.doi.org/10.4049/jimmunol.1101772; PMID: 21880981
   PubMed Web of Science ®Google Scholar
• Paranjape T, Slack FJ, Weidhaas JB. MicroRNAs: tools for cancer diagnostics. Gut 2009; 58:1546 - 54; http://dx.doi.org/10.1136/gut.2009.179531; PMID: 19834118
   PubMed Web of Science ®Google Scholar
• Xiao B, Zhu ED, Li N, Lu DS, Li W, Li BS, et al. Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis. Oncol Rep 2012; 27:559 - 66; PMID: 22020746
   PubMed Web of Science ®Google Scholar
• Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010; 11:136 - 46; http://dx.doi.org/10.1016/S1470-2045(09)70343-2; PMID: 20022810
   PubMed Web of Science ®Google Scholar
• Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol 2009; 34:537 - 42; PMID: 19148490
   PubMed Web of Science ®Google Scholar
• Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui J, et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol 2011; 22:2257 - 66; http://dx.doi.org/10.1093/annonc/mdq758; PMID: 21343377
   PubMed Web of Science ®Google Scholar
• Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 2011; 17:2725 - 33; http://dx.doi.org/10.1158/1078-0432.CCR-10-2132; PMID: 21220473
   PubMed Web of Science ®Google Scholar
• Feng R, Chen X, Yu Y, Su L, Yu B, Li J, et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 2010; 298:50 - 63; http://dx.doi.org/10.1016/j.canlet.2010.06.004; PMID: 20619534
   PubMed Web of Science ®Google Scholar
• Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 2010; 6:e1000879; http://dx.doi.org/10.1371/journal.pgen.1000879; PMID: 20300657
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu W, Zhang J, Huo S, Zhou L, Gu Z, et al. MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity. Biochem Biophys Res Commun 2010; 395:275 - 80; http://dx.doi.org/10.1016/j.bbrc.2010.04.005; PMID: 20381459
   PubMed Web of Science ®Google Scholar
• Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123:372 - 9; http://dx.doi.org/10.1002/ijc.23501; PMID: 18449891
   PubMed Web of Science ®Google Scholar
• Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012; 69:723 - 31; http://dx.doi.org/10.1007/s00280-011-1752-3; PMID: 21993663
   PubMed Web of Science ®Google Scholar
• Wang F, Sun GP, Zou YF, Hao JQ, Zhong F, Ren WJ. MicroRNAs as promising biomarkers for gastric cancer. Cancer Biomark 2012; 11:259 - 67; PMID: 23248184
   PubMed Web of Science ®Google Scholar
• Sapari NS, Loh M, Vaithilingam A, Soong R. Clinical potential of DNA methylation in gastric cancer: a meta-analysis. PLoS One 2012; 7:e36275; http://dx.doi.org/10.1371/journal.pone.0036275; PMID: 22558417
   PubMed Web of Science ®Google Scholar
• Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 2010; 70:1430 - 40; http://dx.doi.org/10.1158/0008-5472.CAN-09-2755; PMID: 20124475
   PubMed Web of Science ®Google Scholar
• Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006; 12:989 - 95; http://dx.doi.org/10.1158/1078-0432.CCR-05-2096; PMID: 16467114
   PubMed Web of Science ®Google Scholar
• Tahara T, Arisawa T, Shibata T, Wang FY, Nakamura M, Sakata M, et al. Risk prediction of gastric cancer by analysis of aberrant DNA methylation in non-neoplastic gastric epithelium. Digestion 2007; 75:54 - 61; http://dx.doi.org/10.1159/000101775; PMID: 17438355
   PubMed Web of Science ®Google Scholar
• Lu XX, Yu JL, Ying LS, Han J, Wang S, Yu QM, et al. Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression. Cancer 2012; 118:5507 - 17; http://dx.doi.org/10.1002/cncr.27604; PMID: 22576578
   PubMed Web of Science ®Google Scholar
• Shin CM, Kim N, Jung Y, Park JH, Kang GH, Kim JS, et al. Role of Helicobacter pylori infection in aberrant DNA methylation along multistep gastric carcinogenesis. Cancer Sci 2010; 101:1337 - 46; http://dx.doi.org/10.1111/j.1349-7006.2010.01535.x; PMID: 20345486
   PubMed Web of Science ®Google Scholar
• Paluszczak J, Baer-Dubowska W. Epigenetic diagnostics of cancer--the application of DNA methylation markers. J Appl Genet 2006; 47:365 - 75; http://dx.doi.org/10.1007/BF03194647; PMID: 17132902
   PubMed Web of Science ®Google Scholar
• Shivapurkar N, Gazdar AF. DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med 2010; 10:123 - 32; http://dx.doi.org/10.2174/156652410790963303; PMID: 20196733
   PubMed Web of Science ®Google Scholar
• Yamashita K, Sakuramoto S, Watanabe M. Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surg Today 2011; 41:24 - 38; http://dx.doi.org/10.1007/s00595-010-4370-5; PMID: 21191688
   PubMed Web of Science ®Google Scholar
• Kaise M, Miwa J, Fujimoto A, Tashiro J, Tagami D, Sano H, et al. Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: serum trefoil factor 3 is a stable biomarker. Gastric Cancer 2012; In press http://dx.doi.org/10.1007/s10120-012-0185-y; PMID: 22907485
   PubMed Web of Science ®Google Scholar
• Kato K, Iida S, Uetake H, Takagi Y, Yamashita T, Inokuchi M, et al. Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer 2008; 122:603 - 8; http://dx.doi.org/10.1002/ijc.23143; PMID: 17943730
   PubMed Web of Science ®Google Scholar
• McLean MH, El-Omar EM. Genetics of inflammation in the gastrointestinal tract and how it can cause cancer. Recent Results Cancer Res 2011; 185:173 - 83; http://dx.doi.org/10.1007/978-3-642-03503-6_11; PMID: 21822827
   PubMedGoogle Scholar
• Arnold IC, Lee JY, Amieva MR, Roers A, Flavell RA, Sparwasser T, et al. Tolerance rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia. Gastroenterology 2011; 140:199 - 209; http://dx.doi.org/10.1053/j.gastro.2010.06.047; PMID: 20600031
   PubMed Web of Science ®Google Scholar
• Müller A, Solnick JV. Inflammation, immunity, and vaccine development for Helicobacter pylori.. Helicobacter 2011; 16:Suppl 1 26 - 32; http://dx.doi.org/10.1111/j.1523-5378.2011.00877.x; PMID: 21896082
   PubMed Web of Science ®Google Scholar
• Persson C, Canedo P, Machado JC, El-Omar EM, Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol 2011; 173:259 - 70; http://dx.doi.org/10.1093/aje/kwq370; PMID: 21178102
   PubMed Web of Science ®Google Scholar
• Castaño-Rodríguez N, Kaakoush NO, Goh KL, Fock KM, Mitchell HM. The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case-control study and meta-analysis. PLoS One 2013; 8:e60327; http://dx.doi.org/10.1371/journal.pone.0060327; PMID: 23565226
   PubMedGoogle Scholar
• Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007; 132:905 - 12; http://dx.doi.org/10.1053/j.gastro.2006.12.026; PMID: 17324405
   PubMed Web of Science ®Google Scholar
• Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol 2008; 154:360 - 4; http://dx.doi.org/10.1111/j.1365-2249.2008.03776.x; PMID: 18826495
   PubMed Web of Science ®Google Scholar
• Kara B, Akkiz H, Doran F, Bayram S, Erken E, Gumurdullu Y, et al. The significance of E266K polymorphism in the NOD1 gene on Helicobacter pylori infection: an effective force on pathogenesis?. Clin Exp Med 2010; 10:107 - 12; http://dx.doi.org/10.1007/s10238-009-0077-6; PMID: 19882212
   PubMed Web of Science ®Google Scholar
• El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398 - 402; http://dx.doi.org/10.1038/35006081; PMID: 10746728
   PubMed Web of Science ®Google Scholar
• El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124:1193 - 201; http://dx.doi.org/10.1016/S0016-5085(03)00157-4; PMID: 12730860
   PubMed Web of Science ®Google Scholar
• Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol 2010; 25:1604 - 17; http://dx.doi.org/10.1111/j.1440-1746.2010.06428.x; PMID: 20880168
   PubMed Web of Science ®Google Scholar
• Gorouhi F, Islami F, Bahrami H, Kamangar F. Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer 2008; 98:1443 - 51; http://dx.doi.org/10.1038/sj.bjc.6604277; PMID: 18319718
   PubMed Web of Science ®Google Scholar
• Partida-Rodríguez O, Torres J, Flores-Luna L, Camorlinga M, Nieves-Ramírez M, Lazcano E, et al. Polymorphisms in TNF and HSP-70 show a significant association with gastric cancer and duodenal ulcer. Int J Cancer 2010; 126:1861 - 8; PMID: 19626584
   PubMed Web of Science ®Google Scholar
• Xue H, Liu J, Lin B, Wang Z, Sun J, Huang G. A meta-analysis of interleukin-8 -251 promoter polymorphism associated with gastric cancer risk. PLoS One 2012; 7:e28083; http://dx.doi.org/10.1371/journal.pone.0028083; PMID: 22279522
   PubMed Web of Science ®Google Scholar
• Xue H, Wang YC, Lin B, An J, Chen L, Chen J, et al. A meta-analysis of interleukin-10 -592 promoter polymorphism associated with gastric cancer risk. PLoS One 2012; 7:e39868; http://dx.doi.org/10.1371/journal.pone.0039868; PMID: 22859944
   PubMedGoogle Scholar
• Xue H, Lin B, An J, Zhu Y, Huang G. Interleukin-10-819 promoter polymorphism in association with gastric cancer risk. BMC Cancer 2012; 12:102; http://dx.doi.org/10.1186/1471-2407-12-102; PMID: 22436502
   PubMed Web of Science ®Google Scholar
• Ni P, Xu H, Xue H, Lin B, Lu Y. A meta-analysis of interleukin-10-1082 promoter polymorphism associated with gastric cancer risk. DNA Cell Biol 2012; 31:582 - 91; http://dx.doi.org/10.1089/dna.2011.1440; PMID: 22335769
   PubMed Web of Science ®Google Scholar
• Leja M, Wex T, Malfertheiner P. Markers for gastric cancer premalignant lesions: where do we go?. Dig Dis 2012; 30:268 - 76; http://dx.doi.org/10.1159/000336990; PMID: 22722551
   PubMed Web of Science ®Google Scholar
• Arnold JN, Saldova R, Galligan MC, Murphy TB, Mimura-Kimura Y, Telford JE, et al. Novel glycan biomarkers for the detection of lung cancer. J Proteome Res 2011; 10:1755 - 64; http://dx.doi.org/10.1021/pr101034t; PMID: 21214223
   PubMed Web of Science ®Google Scholar
• Kirmiz C, Li BS, An HJ, Clowers BH, Chew HK, Lam KS, et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics 2007; 6:43 - 55; http://dx.doi.org/10.1074/mcp.M600171-MCP200; PMID: 16847285
   PubMed Web of Science ®Google Scholar
• Ruhaak LR, Miyamoto S, Lebrilla CB. Developments in the identification of glycan biomarkers for the detection of cancer. Mol Cell Proteomics 2013; 12:846 - 55; http://dx.doi.org/10.1074/mcp.R112.026799; PMID: 23365456
   PubMed Web of Science ®Google Scholar
• Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 2011; 21:195 - 205; http://dx.doi.org/10.1093/glycob/cwq147; PMID: 20861084
   PubMed Web of Science ®Google Scholar
• Uen YH, Lin KY, Sun DP, Liao CC, Hsieh MS, Huang YK, et al. Comparative proteomics, network analysis and post-translational modification identification reveal differential profiles of plasma Con A-bound glycoprotein biomarkers in gastric cancer. J Proteomics 2013; 83:197 - 213; http://dx.doi.org/10.1016/j.jprot.2013.03.007; PMID: 23541716
   PubMed Web of Science ®Google Scholar
• Gomes C, Almeida A, Ferreira JA, Silva L, Santos-Sousa H, Pinto-de-Sousa J, et al. Glycoproteomic analysis of serum from patients with gastric precancerous lesions. J Proteome Res 2013; 12:1454 - 66; http://dx.doi.org/10.1021/pr301112x; PMID: 23312025
   PubMed Web of Science ®Google Scholar
• Weyers A, Yang B, Park JH, Kim YS, Kim SM, Lee SE, et al. Microanalysis of stomach cancer glycosaminoglycans. Glycoconj J 2013; http://dx.doi.org/10.1007/s10719-013-9476-8; PMID: 23604988
   PubMed Web of Science ®Google Scholar
• Walker MR, Lund J, Thompson KM, Jefferis R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J 1989; 259:347 - 53; PMID: 2524188
   PubMed Web of Science ®Google Scholar
• Bones J, Byrne JC, O’Donoghue N, McManus C, Scaife C, Boissin H, et al. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res 2011; 10:1246 - 65; http://dx.doi.org/10.1021/pr101036b; PMID: 21142185
   PubMed Web of Science ®Google Scholar
• Kodar K, Stadlmann J, Klaamas K, Sergeyev B, Kurtenkov O. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J 2012; 29:57 - 66; http://dx.doi.org/10.1007/s10719-011-9364-z; PMID: 22179780
   PubMed Web of Science ®Google Scholar
• Kanoh Y, Mashiko T, Danbara M, Takayama Y, Ohtani S, Egawa S, et al. Changes in serum IgG oligosaccharide chains with prostate cancer progression. Anticancer Res 2004; 24:5B 3135 - 9; PMID: 15510601
   PubMedGoogle Scholar
• Gerçel-Taylor C, Bazzett LB, Taylor DD. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer. Gynecol Oncol 2001; 81:71 - 6; http://dx.doi.org/10.1006/gyno.2000.6102; PMID: 11277653
   PubMed Web of Science ®Google Scholar
• Wu W, Chung MC. The gastric fluid proteome as a potential source of gastric cancer biomarkers. J Proteomics 2013; In press http://dx.doi.org/10.1016/j.jprot.2013.04.035; PMID: 23665003
   PubMed Web of Science ®Google Scholar
• Chong PK, Lee H, Loh MC, Choong LY, Lin Q, So JB, et al. Upregulation of plasma C9 protein in gastric cancer patients. Proteomics 2010; 10:3210 - 21; http://dx.doi.org/10.1002/pmic.201000127; PMID: 20707004
   PubMed Web of Science ®Google Scholar
• Cohen M, Yossef R, Erez T, Kugel A, Welt M, Karpasas MM, et al. Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. PLoS One 2011; 6:e14540; http://dx.doi.org/10.1371/journal.pone.0014540; PMID: 21267442
   PubMed Web of Science ®Google Scholar
• Chan AO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, et al. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 2001; 48:808 - 11; http://dx.doi.org/10.1136/gut.48.6.808; PMID: 11358900
   PubMed Web of Science ®Google Scholar
• Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer. Oncology 1999; 56:253 - 8; http://dx.doi.org/10.1159/000011973; PMID: 10202282
   PubMed Web of Science ®Google Scholar
• Tanaka K, Miki C, Wakuda R, Kobayashi M, Tonouchi H, Kusunoki M. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scand J Gastroenterol 2004; 39:754 - 60; http://dx.doi.org/10.1080/00365520410005973; PMID: 15513361
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O. Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer. Gastric Cancer 2009; 12:31 - 6; http://dx.doi.org/10.1007/s10120-008-0494-3; PMID: 19390929
   PubMed Web of Science ®Google Scholar
• Wu W, Juan WC, Liang CR, Yeoh KG, So J, Chung MC. S100A9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis. Proteomics Clin Appl 2012; 6:152 - 62; http://dx.doi.org/10.1002/prca.201100050; PMID: 22532451
   PubMed Web of Science ®Google Scholar
• Lin LL, Huang HC, Juan HF. Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics 2012; 75:3081 - 97; http://dx.doi.org/10.1016/j.jprot.2012.03.046; PMID: 22498886
   PubMed Web of Science ®Google Scholar
• Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007; 1:1 - 48; PMID: 19690635
   PubMedGoogle Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442; http://dx.doi.org/10.1371/journal.pmed.0030442; PMID: 17132052
   PubMed Web of Science ®Google Scholar
• Rizzato C, Kato I, Plummer M, Muñoz N, Stein A, Jan van Doorn L, et al. Risk of advanced gastric precancerous lesions in Helicobacter pylori infected subjects is influenced by ABO blood group and cagA status. Int J Cancer 2013; 133:315 - 22; http://dx.doi.org/10.1002/ijc.28019; PMID: 23319424
   PubMed Web of Science ®Google Scholar
• Lofgren JL, Whary MT, Ge Z, Muthupalani S, Taylor NS, Mobley M, et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology 2011; 140:210 - 20; http://dx.doi.org/10.1053/j.gastro.2010.09.048; PMID: 20950613
   PubMed Web of Science ®Google Scholar